



Clinical Practice Guideline Peninsula Care Goal

Indications for Antenatal Ultrasound Safe

Purpose

The purpose of this guideline is to assist in identifying women who's pregnancies are at greater risk of growth restriction or adverse outcomes, and to provide an appropriate template for the frequency of ultrasound in women at higher risk. The summary is derived from a combination of local, national and international guidelines.

Scope

The guideline may involve medical staff in O&G, midwives, sonographers, radiologists.

Definitions

| | |
|----------------|---|
| AC | Abdominal circumference |
| APH | Antepartum Haemorrhage |
| ASUM | Australian Society for Ultrasound in Medicine |
| BMI | Body mass index |
| BPD | Bi-parietal diameter |
| BPP | Biophysical profile (liquor volume, tone, movement, breathing movements and CTG) |
| CRL | Crown-rump length |
| DV | Ductus venosus flow |
| EDF | End diastolic flow |
| FGR | Fetal growth restriction |
| FL | Femur length |
| FVL | Factor V Leiden |
| Growth | Physical fetal measurements that include BPD, HC, AC and FL |
| HC | Head circumference |
| LV | Liquor volume |
| MCA PI | Middle cerebral artery pulsatility dopplers |
| MCA PSV | Middle cerebral artery peak systolic velocity (indication of fetal anaemia) |
| PAPP-A | Pregnancy associated plasma protein |
| PGM | Prothrombin gene mutation |
| PI | Pulsatility index (systolic-diastolic)/mean flow over the cycle length |
| RCOG | Royal College of Obstetricians and Gynaecologists |
| SFH | Symphiso-fundal height |
| UAD | Umbilical artery dopplers |
| US | Ultrasound |

Indications

All women should be screened for risk factors for fetal growth restriction as part of the antenatal booking visit and any existing or new risk factors should be considered at each subsequent visit. Regular ultrasound for women with risk factors will help to detect signs of fetal growth restriction and is recommended as part of a more global strategy to reduce rates of stillbirth.

Contraindications

Women who decline ultrasound examinations should have a discussion with an obstetric consultant regarding the pros and cons of this decision. This discussion must be documented in the medical records.

| | | |
|------------------------------------|------------------------------|---------------------------|
| PROMPT doc no: 125382 Version: 6.0 | | |
| First created: 15/06/2017 | Page 1 of 6 | Last reviewed: 04/05/2023 |
| Version changed: 04/05/2023 | UNCONTROLLED WHEN DOWNLOADED | Next review: 30/06/2023 |

Clinical Practice Guideline Indications for Antenatal Ultrasound

Peninsula Care Goal Safe

Guideline

- All clinicians should be mindful of the indications for antenatal ultrasound, and the risk factors that require more intensive ultrasound assessment.
- A risk assessment should be performed at booking by the booking midwife. This risk assessment must be discussed with the woman and documented in BOS and the Victorian Medical Records (VMR) as level 1, 2 or 3 (see table below).
- Risk factors for FGR must also inform the appropriate model of care (see [Risk Assessment for Model of Pregnancy Care](#)) with an obstetric booking visit to be arranged prior to 16/40 for women in group B or C and for women where the model of care is uncertain.
- The risk of fetal growth restriction must be considered at each antenatal visit, especially where new risk factors may have developed, and re-documented in BOS and VMR if that risk level has changed.
- Women who may benefit from low dose Aspirin should commence it prior to 16/40. The dose can be taken as either 100mg daily, which can be bought from any pharmacy, or 150mg daily, taken by halving a 300mg tablet. Low dose Aspirin is safe in pregnancy but medical contraindications should be considered.
- Contraindications to aspirin include: Allergy or sensitivity to aspirin or NSAIDs, active peptic ulcer disease, active bleeding or bleeding tendency, pregnancy after 36/40.

The accompanying chart is for the guidance of clinicians. Modification of the recommended frequency of scans may be required depending on the individual circumstances of the pregnant woman.

The obstetrician in the antenatal clinic or on the Women's Health Unit is responsible for arranging the ultrasound. The indication for the ultrasound must be clearly outlined on the request. Appropriate follow up is to be arranged to review and discuss the results of the ultrasound and discuss any further management.

Guideline for Shared Care GPs

GPs should assess risk factors for fetal growth restriction at the woman's first antenatal visit. Due to their early involvement in women's care, and the clinical benefit of starting treatment prior to 16 weeks, GPs are able to recommend that women with risk factors for pre-eclampsia or FGR commence low dose aspirin 100 or 150mg daily. Contraindications to low dose Aspirin are same as in the general population (known allergy or sensitivity to aspirin, active peptic ulcer disease, bleeding disorders, active bleeding). Aspirin should be stopped at 36/40.

Women with risk factors for fetal growth restriction should have this discussed with them and an early referral for antenatal booking. Any risk factors should be documented in the referral letter.

Evaluation

Effectiveness of this guideline will be monitored and evaluated through:

Review of babies with a birth weight below the 3rd centile at 40wks (Victorian state KPI)

Audit of the identification of risk and appropriate management plan as documented in the medical records.

Audit of the frequency of ultrasound scans performed for women with risk factors.

| | | |
|---------------------------------------|------------------------------|---------------------------|
| PROMPT doc no: 125382 Version: 6.0 | | |
| First created: 15/06/2017 | Page 2 of 6 | Last reviewed: 04/05/2023 |
| Version changed: 04/05/2023 | UNCONTROLLED WHEN DOWNLOADED | Next review: 30/06/2023 |



Clinical Practice Guideline Peninsula Care Goal

Indications for Antenatal Ultrasound Safe

Key Aligned Documents

[Management of Pregnancy & Childbirth for Women with a BMI >35,](#)

[Twin Pregnancy,](#)

[Cholestasis of Pregnancy,](#)

[Decreased Fetal Movements](#)

[Diabetes in Pregnancy,](#)

[Management of the Small for Gestational Age or Growth Restricted Fetus,](#)

[Risk Assessment for Model of Pregnancy Care,](#)

[Management of Women with a BMI ≥35 in Pregnancy](#)

References

ASUM. Guidelines, Policies and Statements, D2, Statement on the Mid Trimester Obstetric Scan Revised September 2014

The Investigation and Management of The Small for Gestational Age Fetus. RCOG Green Top Guideline 31. January 2014

Measurement of Cervical Length for Prediction of Preterm Birth. RANZCOG College Statement C-Obs 27. July 2012

Inherited Thrombophilias in Pregnancy. Up To Date 2016

Detection and Management of Women with Fetal Growth Restriction in Singleton Pregnancies. [Position Statement. Stillbirth Centre of Research Excellence](#). 2019

Appendix

Guide to Antenatal Ultrasound Assessment

| Document management | Position |
|--|---------------------------------------|
| Executive Sponsor: | Executive Director Frankston Hospital |
| Document Owner: | Clinical Director Women's Health |
| Document Author | Clinical Director Women's Health |
| Approved by: | Women's Health Executive |
| Date created/revised in archived system: | Created 15/06/2017 Revised 13/01/2020 |

Guide to Antenatal Ultrasound Assessment

Routine Assessment (not to be booked for Peninsula Health US)

| Indication | Parameter | Timing | Reference |
|--|---------------------------------|---------------------------|--------------------|
| Dating scan | CRL | 1 st Trimester | |
| First trimester screening | CRL, Nuchal Lucency, Nasal Bone | 11-13+6 wks | |
| Fetal anatomy scan | See guideline | 18-22/40 wks | ASUM Guideline D2 |
| Placental localisation (if low at anatomy scan) | Distance from placenta to os | 32 wks | ASUM Guideline D12 |
| Mild fetal renal pelvic dilatation | Growth, renal pelvis | 32 wks | |

Risk Assessment for FGR (to be documented at booking and reviewed each subsequent visit)

| Level 1 | Level 2 | | Level 3 |
|--|---|---|---|
| No FGR risk factors identified^A One minor risk factor with normal clinical growth^{A/B} Note: more than 50% of FGR cases have no risk factors | 2 or more minor risk factors <ul style="list-style-type: none"> Age ≥ 35 yrs^B Nulliparity^A IVF singleton pregnancy^B Aboriginal or Torres Strait Islander^A Smoking ≤ 10/day BMI 30 to 34 kg/m² ^{A/B} BMI < 18 kg/m² OR <ul style="list-style-type: none"> Previous late ($\geq 32/40$) FGR or pre-eclampsia^B Advise low dose Aspirin 150mg nocte prior to 16/40 up to 36/40 | Antenatal Complications <ul style="list-style-type: none"> Suspected FGR/SGA (SFH > 2 cm behind projected fundal height, static growth, SFH $< 10^{\text{th}}$ %)^B Arrange US fetal growth. If growth normal but ongoing clinical suspicion, arrange FU growth assessment. | High Risk of Early FGR^C <ul style="list-style-type: none"> Maternal age ≥ 40 yrs Smoker > 10/day, substance use Previous early ($< 32/40$) FGR/SGA or pre-eclampsia PAPP-A < 0.4 MoM Congenital CMV Pre-eclampsia or hypertension APH heavier than menstrual loss Previous stillbirth with FGR/SGA Maternal medical conditions (eg antiphospholipid syndrome, renal impairment, diabetes with vascular disease, chronic inflammatory conditions) BMI ≥ 35 kg/m² ^{A/B} * |
| Standardised serial SFH at each visit from 24/40 Plot SFH on growth chart | US fetal growth at 28 and 34-36 wks Review model of care group (see CPG) | | Advise low dose aspirin (150mg nocte) prior to 16/40 up to 36/40 Review model of care (see CPG) US growth 4 weekly from 24/40 * BMI ≥ 35 see CPG US growth/AFI/Doppler 28, 32, 36 weeks |

A/B/C denotes relevant model of care – see [Risk Assessment for Model of Pregnancy Care](#) CPG

Ongoing Assessment of High Risk Pregnancies

| Indication | Parameter | Timing | Reference |
|---|------------------------|---|---|
| Pregnancy Induced Hypertension | Growth, LV, UA | 2-4 weekly if stable | Peninsula Health CPG |
| Pre-eclampsia | Growth, LV, UA | 2 weekly if normal | Peninsula Health CPG |
| FGR (EFW or AC <10th%, normal Dopplers) Deliver: >34/40 if static growth by 37+6 if MCA PI<5 th % by 38+6 if normal dopplers | Growth, LV, UA, MCA PI | 2 weekly if normal Weekly UA and MCA from 36/40 | RCOG Guideline 31 Peninsula Health CPG |
| FGR (impaired UAD or MCA, EDV present) Deliver: >34/40 if static growth by 37/40 if UA>95 th % or CPR<5 th % | Growth, LV, UA, MCA PI | Twice weekly UA, MCA PI, LV 2 weekly growth | RCOG Guideline 31 |
| FGR (absent or REDV) <32/40 refer, 32/40 deliver | Growth, LV, UA, DV | Daily UA, DV | RCOG Guideline 31 |
| Preterm ruptured membranes | Growth, LV | 2 weekly growth, weekly LV | |
| Reduced fetal movements (persistent) | Growth, LV, BPP | If persistently reduced FM or non-reassuring but non-sinister CTG | Peninsula Health CPG |

Routine Screening of High Risk Pregnancies

| Indication | Parameter | Timing | Reference |
|---|------------------------------|--|----------------------|
| Gestational diabetes (diet controlled) | Growth, LV | 32wks (+36 only if macrosomia suspected or poor control) | Peninsula Health CPG |
| Gestational diabetes (treatment) | Growth, LV | 32, 36 wks | Peninsula Health CPG |
| Insulin dependent or type II diabetes | Growth, LV | 28, 32, 36 wks | Peninsula Health CPG |
| Monochorionic twins | Growth, LV, Bladder, MCA PSV | 2 weekly from 16 wks | RANZCOG (C-Obs 42) |
| Dichorionic twins | Growth, LV | 24, 28, 31, 34, 36 wks | Peninsula Health CPG |
| Inherited Thrombophilia (FVL, PGM etc) | | Only if other risk factors | Up To Date 2016 |
| Previous preterm birth | Cervical length | 20 wks (sooner if mid-tri loss) | RANZCOG (C-Obs 27) |
| Obstetric cholestasis | Growth, LV, UA | 2 weekly growth, weekly dopplers | Peninsula Health CPG |
| Breech (pre ECV) | Growth, LV | 36-37wks | Peninsula Health CPG |
| Unable to assess FH due to fibroids | Growth, LV | 4 weekly from 28wks | Peninsula Health CPG |

Abbreviations:

| | | | |
|--------|--|---------|--|
| AC | Abdominal circumference | IUGR | Intrauterine growth restriction |
| APH | Antepartum Haemorrhage | LV | Liquor volume |
| ASUM | Australian Society for Ultrasound in Medicine | MCA PI | Middle cerebral artery pulsatility dopplers |
| BMI | Body mass index | MCA PSV | Middle cerebral artery peak systolic velocity |
| BPD | Bi-parietal diameter | | (indication of fetal anaemia) |
| BPP | Biophysical profile (liquor volume, tone, movement, breathing movements and CTG) | PAPP-A | Pregnancy associated plasma protein |
| CRL | Crown–rump length | PGM | Prothrombin gene mutation |
| DV | Ductus venosus flow | PI | Pulsatility index (systolic–diastolic)/mean flow over the cycle length |
| EDF | End diastolic flow | RCOG | Royal college of Obstetricians and Gynaecologists |
| FGR | Fetal growth restriction | SGA | Small for gestational age |
| FL | Femur length | SFH | Symphyso-fundal height |
| FVL | Factor V leiden | UAD | Umbilical artery dopplers |
| Growth | Physical fetal measurements: BPD, HC, AC and FL | US | Ultrasound |
| HC | Head circumference | | |

References:

ASUM. Guidelines, Policies and Statements, D2, Statement on the Mid Trimester Obstetric Scan Revised September 2014

Management of Pregnancy & Childbirth for Women with a BMI >35, Peninsula Health CPG. 2015

Twin Pregnancy, Peninsula Health CPG.

Cholestasis of Pregnancy, Peninsula Health CPG.

Reduced Fetal Movement, Peninsula Health CPG.

Diabetes in Pregnancy, Peninsula Health CPG

Risk Assessment for Model of Pregnancy Care, Peninsula Health CPG

Low Dose Aspirin Use During Pregnancy. [ACOG Committee Opinion](#). 743. July 2018

The Investigation and Management of The Small for Gestational Age Fetus. [RCOG Green Top Guideline 31. January 2014](#)

Measurement of Cervical Length for Prediction of Preterm Birth. RANZCOG College Statement C-Obs 27. July 2012

Inherited Thrombophilias in Pregnancy. Up To Date 2016

Detection and Management of Women with Fetal Growth Restriction in Singleton Pregnancies. [Stillbirth Centre of Research Excellence](#).